Our Fisher Clinical ServicesSM offerings are now part of the Patheon brand portfolio by Thermo Fisher Scientific. Please update your bookmark.
Vectoring In – Viral Vector Video Series
When you are poised to ramp up late stage manufacturing to go commercial, you’ll need to be able to count on your CDMO for a great deal more than capacity. You may be wondering what should you know in order to get ready for late-phase approval and commercialization.
In this Vectoring In video series, our experts will talk you through key questions you and your CDMO need to be able to answer so you can be confident you’ll be ready for late phase approval and commercialization.
Part 1: Avoiding CMC Delays in Cell & Gene Therapies
In this video, Steve Falcone (VP of Quality for Viral Vector Services) discusses the importance of the development part of a CDMO provider and how it can help with your project.
Part 2: What Regulators are Looking for in Cell & Gene Therapy Submissions
In this video, Steve continues the conversation discussing the foundational aspects of your submissions and why luck isn’t the best strategy.
Part 3: Bypassing Late-Phase Viral Vector Process Speed Bumps
In this video, Akanksha Nagpal (Senior Director, Bioprocess Development for Viral Vector Services) talks about different scenarios that pop up in late-phase.
Part 4: Accelerating Late Phase Development
In this video, Akanksha continues the conversation by discussing how to increase your chances of right first time by leveraging the experience of your CDMO.
Together with a collaborative partner that knows the right questions to ask – from manufacturing to supply chain – you can develop the commercial-ready process you need to succeed with investors and patients.
Do you have any questions, and would like to speak to our experts?
Contact Us and we will reach out to schedule a meeting